Literature DB >> 10799161

Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer.

M P Raitanen1, T Marttila, E Kaasinen, E Rintala, R Aine, T L Tammela.   

Abstract

PURPOSE: We compared the sensitivity of the BTA statdagger test, a rapid, noninvasive, qualitative urine test that detects bladder tumor associated antigen (human complement factor H related protein) in urine, to that of voided urine cytology in patients with primary bladder cancer. We also assessed the effect of tumor size, number, histological grade and stage on test sensitivity.
MATERIALS AND METHODS: We evaluated 151 patients with newly diagnosed bladder cancer in a prospective multicenter study. A voided urine sample obtained before transurethral bladder tumor resection was divided for culture, cytology and BTA stat testing.
RESULTS: Overall sensitivity of the BTA stat test and urine cytology for detecting primary bladder cancer was 81.5% and 30.3%, respectively (p <0.0001). The sensitivity of each test increased as tumor size, number, histological grade and stage increased.
CONCLUSIONS: Sensitivity of the BTA stat test was superior to that of voided urine cytology in all tumor categories. This noninvasive, easy to perform, point of care test may have the potential to replace cytology for diagnosing bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799161

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.

Authors:  Mika-P Raitanen
Journal:  World J Urol       Date:  2008-01-08       Impact factor: 4.226

2.  Urine cytology and adjunct markers for detection and surveillance of bladder cancer.

Authors:  Peggy S Sullivan; Jessica B Chan; Mary R Levin; Jianyu Rao
Journal:  Am J Transl Res       Date:  2010-07-25       Impact factor: 4.060

3.  Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.

Authors:  D Chao; S J Freedland; A J Pantuck; A Zisman; A S Belldegrun
Journal:  Rev Urol       Date:  2001

Review 4.  Alternatives to cytology in the management of non-muscle invasive bladder cancer.

Authors:  Gilad E Amiel; Tung Shu; Seth P Lerner
Journal:  Curr Treat Options Oncol       Date:  2004-10

5.  Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis.

Authors:  Aiye Guo; Xiuhua Wang; Lan Gao; Juan Shi; Changyi Sun; Zhen Wan
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

6.  Prognostic utility of human complement factor H related protein test (the BTA stat Test).

Authors:  M P Raitanen; E Kaasinen; E Rintala; E Hansson; P Nieminen; R Aine; T L Tammela
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

7.  Utility of urine cytology in evaluating hematuria with sonographically suspected bladder lesion in patients older than 50 years.

Authors:  Hussam Eldin Helmy Mady; Abd Alhady Mohammad Omar; Mohamed Abd-Alla Elgammal; Ghada Hosny Mohamed Ibrahim
Journal:  Urol Ann       Date:  2014-07

8.  Inhibition of Lon blocks cell proliferation, enhances chemosensitivity by promoting apoptosis and decreases cellular bioenergetics of bladder cancer: potential roles of Lon as a prognostic marker and therapeutic target in baldder cancer.

Authors:  Yongzhang Liu; Linhua Lan; Kate Huang; Rongrong Wang; Cuicui Xu; Yang Shi; Xiaoyi Wu; Zhi Wu; Jiliang Zhang; Lin Chen; Lu Wang; Xiaomin Yu; Haibo Zhu; Bin Lu
Journal:  Oncotarget       Date:  2014-11-30

Review 9.  Novel non invasive diagnostic strategies in bladder cancer.

Authors:  Anamaria Truta; Tudor Adrian Hodor Popon; George Saraci; Liviu Ghervan; Ioan Victor Pop
Journal:  Clujul Med       Date:  2016-04-15

10.  The utility of fluorescence in situ hybridization for detection of bladder urothelial carcinoma in routine clinical practice.

Authors:  Kyung Won Kwak; Sun Hee Kim; Hyun Moo Lee
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.